TGFB1 and scleroderma: Taiji et al. [31] reported that the IL-17A signaling pathway took an antifibrogenic effect in scleroderma fibroblasts as intrinsic activation of TGF-β1 inhibits IL-17A signaling by the down-regulation of the receptor and contributed to the excess collagen accumulation and tissue fibrosis via miR-129-5p.